Wisdom, Amy J. http://orcid.org/0000-0002-6098-5353
Mowery, Yvonne M. http://orcid.org/0000-0002-9839-2414
Hong, Cierra S.
Himes, Jonathon E.
Nabet, Barzin Y.
Qin, Xiaodi
Zhang, Dadong
Chen, Lan
Fradin, Hélène http://orcid.org/0000-0003-4110-0983
Patel, Rutulkumar
Bassil, Alex M.
Muise, Eric S. http://orcid.org/0000-0002-1238-5118
King, Daniel A.
Xu, Eric S. http://orcid.org/0000-0001-9933-9386
Carpenter, David J. http://orcid.org/0000-0002-9261-7168
Kent, Collin L.
Smythe, Kimberly S. http://orcid.org/0000-0002-2329-8298
Williams, Nerissa T.
Luo, Lixia
Ma, Yan
Alizadeh, Ash A. http://orcid.org/0000-0002-5153-5625
Owzar, Kouros
Diehn, Maximilian http://orcid.org/0000-0003-2032-0581
Bradley, Todd
Kirsch, David G. http://orcid.org/0000-0002-2086-205X
Article History
Received: 18 September 2020
Accepted: 2 November 2020
First Online: 17 December 2020
Competing interests
: D.G.K. is a cofounder of XRAD Therapeutics, which is developing radiosensitizers. D.G.K. and Y.M.M. are recipients of a Stand Up To Cancer (SU2C) MSD Catalyst Grant studying pembrolizumab and radiation therapy in sarcoma patients. D.G.K. has received research funding from XRAD Therapeutics, Eli Lilly & Co., Bristol Myers Squibb, Varian Medical Systems, and served as chair of the Developmental Therapeutics Committee for the Sarcoma Alliance for Research through Collaboration. E.S.M. and L.C. are employees of Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. The other authors declare no competing interests.